Cognitive neuroscientist conducting research in disorders of compulsive consumption - Gut Hormones in Addiction (GHADD). Much of this research is early phase translational experimental medicine - mapping the profile and potential efficacy of medications to modulate brain and behavioural markers in these disorders. Developing key methodologies that particularly exploit cognitive, reward and implicit motivational processes in these disorders - targets for future medication development. Valuable experience working in the pharma industry on early phase translational experimental medicine studies as a cognitive neuroscientist. Based at the Neuropsychopharmacology Unit, Division of Brain Sciences.
et al., 2017, Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals., Addict Biol
et al., 2017, Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence, Neuropsychopharmacology, Vol:42, ISSN:0893-133X, Pages:1049-1057
et al., 2017, Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence (vol 42, pg 1049, 2017), Neuropsychopharmacology, Vol:42, ISSN:0893-133X, Pages:1925-1926
Suckling J, Nestor LJ, 2017, The neurobiology of addiction: the perspective from magnetic resonance imaging present and future, Addiction, Vol:112, ISSN:0965-2140, Pages:360-369
et al., 2016, Smokers and ex-smokers have shared differences in the neural substrates for potential monetary gains and losses., Addict Biol